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except for 1 case. No mutation was detected in p53 exons 5 to 8 in tumors with cytoplasmic p53, suggesting that they express wild-type p53. The data indicate that a cytoplasmic accumulation of wild-type p53 in human primary glioblastomas correlates with a certain intermediate lament protein expression, suggesting that it identi es a certain subset of tumors. Neuro-Oncology 4, 171-178, 2002 (Posted to Neuro-Oncology [serial online], Doc. 01-055, April 10, 2002 I nactivation of the tumor suppressor protein p53 is considered a major risk for acquiring multiple gene lesions, thereby promoting tumor development (Janus et al., 1999; Levine, 1997) . This risk is indicated by the high number (50%) of human tumors associated with mutations in the p53 gene. Most of these mutations (80%) are missense mutations of the central-sequencespecific DNA-binding domain (exons 5-8), impairing contact formation with consensus DNA and thereby preventing transactivation of p53 target genes (Hussain et al., 2000) .
Loss of p53-speci c functions due to mutation seems also to be involved in the development of astrocytic tumors, the most frequent neoplasms of the human CNS (Collins, 1999; Fulci et al., 1998) . Diffusively in ltrating astrocytomas account for more than 60% of all primary brain tumors, and glioblastomas represent the most malignant tumor type within this group (Kleihues and Cavenee, 2000) . p53 mutations are predominantly associated with secondary glioblastomas, tumors that have developed from low-grade astrocytomas (Sidransky et al., 1992) . The mutation in the secondary glioblastoma normally is already present in the primary lesion, indicating that it is acquired early in tumor development. This initial loss of wild-type p53 functions is supposed to be a decisive step that favors the accumulation of deletions and gene ampli cations typical of secondary glioblastomas. In primary (de novo) glioblastoma, the most frequent astrocytic tumor seen in adults, the frequency of p53 mutations is low (10%) (Watanabe et al., 1996) . Nevertheless, primary glioblastomas often react positively with p53 antibodies (Von Eckardstein et al., 1997) . This indicates that most of these tumors express wild-type p53, which accumulates to high levels without suppressing growth or inducing apoptosis. An accumulation of wildtype p53 has also been found in breast carcinomas and in undifferentiated neuroblastomas (Moll et al., 1992) where p53 was localized in the cytoplasm. All these observations suggest that wild-type p53 can be inactivated by a mechanism that is associated with cytoplasmic sequestration of the protein. A cytoplasmic localization of p53 was also reported for glioblastomas, in which it is assumed that certain intracellular conditions rather than the type of p53 mutation may be decisive for the localization (Ali et al., 1994) .
Here we studied the subcellular localization of p53 in primary glioblastomas and its correlation with the expression of astrocyte-speci c IFPs. 3 The results show that a significant number of primary glioblastom as exhibit a cytoplasmic p53 staining reaction. These tumors consistently express the IFP vimentin in addition to GFAP, whereas tumors with nuclear p53 are almost exclusively vimentin negative. The data indicate that the presence of cytoplasmic wild-type p53 in primary glioblastom as correlates with a certain IFP expression pattern typical of an early stage in astrocyte differentiation. The correlation suggests that cytoplasmic wild-type p53 in primary glioblastomas does not occur randomly, but identi es a tumor subset with certain phenotypic markers.
Materials and Methods

Immunohistochemistry
Tumor biopsies were xed in 3% formaldehyde, dehydrated with ethanol, and processed for embedding in paraf n. The tumors selected for this study had been classi ed as glioblastomas according to the World Health Organization classification standards (Kleihues and Cavenee, 2000) . Paraffin sections were dewaxed and rehydrated. Endogenous peroxidase reaction was blocked with 1% H 2 O 2 in ethanol. The sections were coated with 10% normal goat serum (Dako, Hamburg, Germany) and subsequently overlaid with the primary antibody for 60 min at room temperature. Bound primary antibodies were detected with biotinylated goat antimouse or goat antirabbit antibodies (Dianova, Hamburg, Germany) (as bridge antibodies) and soluble complexes of streptavidin and biotinylated horseradish peroxidase (Dako). Diaminobenzidine was used as chromogen. The sections were counterstained with hemalum. p53 was localized with a polyclonal rabbit antiserum developed against a recombinant human wild-type p53 (SAPU, Scotland, U.K.) diluted 1:1000. Vimentin was detected with the monoclonal antibody V9 (Boehringer, Mannheim, Germany); GFAP was traced with the monoclonal antibody 6F2 (Dako). A monoclonal antibody produced against a measles virus structural protein was used as control.
Determination of the Proliferation Index
The Ki-67 proliferation index was determined as described previously (Hagel et al., 1995) . Sections were labeled with the monoclonal antibody MIB-1 (Dako); 200 to 800 cells were counted in 3 to 19 high-power fields (0.0153 mm 2 /field) in the tumor area showing the highest proliferative activity. The proliferation index was calculated as number of labeled tumor cells multiplied by 100 divided by the total number of counted nuclei.
Polymerase Chain Reaction Ampli cation and Sequencing of p53 Exons
DNA was extracted from 8-µm-thick sections of paraf n-embedded tumor tissue using the DNeasy tissue kit (Qiagen, Hilden, Germany). Three to 5 sections of a tumor were deparaf nized with 1 ml n-octane at 65°C for 10 min, centrifuged at 14,000 rpm for 5 min, and repeatedly washed with 100% ethanol. The sections were dried brie y at 37°C, resuspended in 180 µl ATL digestion buffer provided with the kit, and incubated in the presence of Proteinase K at 55°C for 18 h. Subsequently, 200 µl AL buffer from the kit was added, and the probes were further incubated at 70°C for 10 min, then 200 µl absolute ethanol was added, the probes were vortexed, and the DNA was isolated by use of a DNeasy minicolumn. For polymerase chain reaction ampli cation of exons 5-9 of the p53 gene, 3 to 10 µl of the nal DNA preparation was added to a total volume of 100 µl reaction mixture as described previously (Hagel et al., 1996) . The following primer pairs (Mashiyama et al., 1991) were used: for exon 5/6, 5-ACCATGAGCGCTGCTAG AT-39 and 59 -AGTTGCAAACCAGACCT-39 ; for exon 7, 59 -GTGTTATCTCCTAGGTTGGC-39 and 59 -CAAGTG GCTCCTGACCTGGA-39 ; and for exon 8/9, 59 -CCTAT CCTGAGTAGTGGTAA-39 and 59 -CCAAGACTTAGT ACCTGAAG-39 . The polymerase chain reaction product was subjected to agarose gel electrophoresis and automatic sequencing.
Statistical Analysis
An extended Fisher's exact test (Hartung et al., 1999) was used to analyze possible correlations between p53 and vimentin expression or p53 and GFAP expression in sample groups A and B given in Tables 1 and 2 , respectively. The one-sided Fisher's exact test was used to analyze correlations between subcellular localization of p53 and expression of vimentin or GFAP. Statistical analysis with regard to Ki-67 index and patient age was performed with the Kruskal-Wallis test. The calculations were done with SAS V81 software. Immunohistochemical staining on paraf n-embedded tissue sections.
Abbreviations: ND, not done; U, unknown.
Results
p53 Staining Patterns in Randomly Selected Primary Glioblastomas
Immunohistochemical studies were performed on formalin-xed and paraf n-embedded biopsies of tumors identi ed as glioblastomas according to World Health Organization classification standards (Kleihues and Cavenee, 2000) . In the first investigation, 26 samples were randomly selected from the archive ( Table 1 ). All of these tumors showed an astrocytic morphology. In some parts, the growth pattern of the small-cell glioblastomas resembled that of oligodendrogliomas. Sections from solid, nonhemorrhagic areas of the tumor were chosen to evaluate the p53 staining pattern. Endothelial cells in areas of vascularization usually were p53 negative and were used as an internal reference for the speci city of the staining. Of the 26 tumors, 18 (69%) reacted positively with the p53 antiserum. p53 was exclusively nuclear in 12 (46%) of the 26 cases (Fig. 1A ), whereas in 6 cases (23%), a cytoplasmic staining was detected (Fig. 1C) ; this was partially associated with nuclear staining (Fig. 1E ). Eight cases (31%) showed no p53 staining at all. The staining patterns were typical for the entire solid tumor area and not con ned to speci c regions such as the in ltrating edges or areas of vascularization. No certain correlation was found between the staining pattern and the intratumoral level of anaplasia.
Vimentin and GFAP Expression Pattern in Randomly Selected Tumors
Early precursor cells of the glial cell lineage express vimentin. In differentiating astrocytes, this IFP is gradually replaced by GFAP (Lee et al., 2000) . Glioblastomas can express both IFP types (Herpers et al., 1986) . When the tumor samples were probed immunohistochemically for expression of these proteins, a clear correlation was found between p53 localization and the IFP expression pattern (Table 1 ). In tumors with only nuclear p53 staining, the presence of these IFPs varied strongly. Most of the cases (6 cases) were positive only for GFAP. Three of them expressed vimentin, and 1 case was positive for both IFPs. Two cases did not show either of these IFPs. Similarly, a heterogeneous expression of these IFPs was found in p53-negative tumors. Three tumors showed GFAP only; 2 cases expressed vimentin; another 2 cases showed both IFPs; and 1 case was negative for both IFPs. In contrast, all tumors exhibiting cytoplasmic p53 staining were found to be positive for both IFPs. A statistical analysis performed with an extended Fisher's exact test indicated that the probability of vimentin expression was different in the 3 groups (P = 0.0294). As determined with the one-sided Fisher's exact test, samples with cytoplasmic p53 showed a signi cantly higher probability (P = 0.013) of vimentin expression than did samples with only nuclear p53 or samples lacking p53. In contrast, the probability of expressing GFAP was not different in these groups (P = 0.216). Tumors with cytoplasmic p53 did not show a signi cantly higher probability (P = 0.0806) of GFAP expression than did those with nuclear p53 or those lacking p53.
Vimentin and p53 Expression Patterns in GFAPPositive Tumors
The statistical analysis suggested that vimentin is a strong indicator for a cytoplasmic accumulation of p53 in tumors that also express GFAP. To test this assumption, we selected 18 additional paraf n-embedded tumor biopsies that had been identified as GFAP positive in immunohistochemistry. Sections of these tumors were subsequently probed for the presence of p53 and vimentin. As shown in Table 2 , 13 of these cases (72%) reacted positively with the polyclonal p53 antibody. Seven of the 18 cases (38%) showed the presence of p53 in the cytoplasm. Six tumors (33%) revealed an exclusive nuclear p53 staining, whereas 5 cases (28%) did not react at all with p53 antibodies. Except for 1 case, all of the tumors exhibiting only nuclear p53 did not react with vimentin-speci c antibodies. p53-negative tumors separated at nearly equal numbers into those positive for GFAP and those positive for both IFPs. However, all of the tumors with cytoplasmic p53 also contained vimentin. Statistical analysis with the modi ed Fisher's exact test indicated that the probability of expressing vimentin was different in the 3 groups (P = 0.0044). As assayed subsequently with the one-sided Fisher's exact test, the probability of vimentin expression was signicantly higher (P = 0.0038) in the sample group with Fig. 1 . Immunostains of p53 and vimentin on tissue sections from 3 cases of human primary glioblastoma, counterstained with hemalum. Staining of p53 in case no. 11 is exclusively nuclear (A), and labeling of vimentin is con ned to endothelial cells lining the vessels (B, arrows). Tumor cells are vimentin negative. Localization of p53 in multinucleated cells from case no. 27 is exclusively cytoplasmic (C, arrows); labeling of vimentin is also shown (D). Cytoplasmic localization of p53 is partially combined with a nuclear staining reaction (E, arrows); vimentin staining is also shown (F). Scale bar = 30 µm. cytoplasmic p53 than in the 2 other groups. No statistically signi cant differences were found between these groups with regard to proliferation index as determined by Ki-67 labeling, cytomorphology, age in years, and survival time.
Mutational Analysis
Although secondary glioblastomas show a high incidence of p53 mutations in exons 5 to 8, mutations are rare in primary glioblastomas. We examined whether the different staining patterns of p53 in relation to that of IFP expression showed any preference for the presence of either wild-type or mutant p53. Genomic DNA was extracted from tumor sections, and the region encoding the DNA-binding domain of p53 was sequenced using primers specific for exons 5 to 8 of the p53 gene. In some cases, sequencing was extended to exon 9 by using primer pairs covering the 59 -end of exon 8 and the 39 -end of exon 9. Exon 9 encompasses the sequence that codes for the major nuclear localization signal (NLS I). As shown in Tables 1 and 2 , none of the tumors with cytoplasmic p53 tested so far exhibited a mutation in these exons. In 1 case (Table 2 , case 27), a single base substitution was found at position 3092, located within intron 8. Mutations were found in some of the primary tumors with exclusive nuclear p53 (Table 1, cases 10, 11, and 14) . The data suggest that tumors with cytoplasmic p53 preferentially express wild-type p53. val-135 from the nucleus, bind it to the vimentin lament system, and subsequently start to proliferate. In contrast, vimentin-de cient cells constantly harbor p53 val-135 in the nucleus and stay in a permanent G 1 arrest. Thus, binding of p53 to the vimentin lament system seems to be tightly connected with an inactivation of its growth regulatory functions. p53 that is cytoplasmic in glioblastomas may also be directly bound to this lament system, which may be essential to escaping a p53-mediated growth arrest. The results obtained with the second GFAP-positive tumor sample group at least give evidence that GFAP alone cannot promote a cytoplasmic accumulation of p53 but demands the presence of vimentin. In the absence of vimentin, p53 was exclusively nuclear.
Cytoplasmic accumulation of wild-type p53 is not a tumor-speci c event but is also found in normal tissues, such as in embryonic stem cells of mice (Sabapathy et al., 1997) , epithelial cells of the basal cell layer in human skin (Spandau, 1994) , and cells lining the mammary duct in lactating tissue (Moll et al., 1992) . In the embryonic brain tissue of rats, p53 mRNA and protein accumulate to high levels in proliferating cells without any indication of apoptosis (Van Lookeren Campagne and Gill, 1998) . Oligodendrocytes explanted from embryonic rat brain exhibit wild-type p53 in the cytoplasm as long as the cells stay in an undifferentiated state. When they achieve the proper stimulus, p53 translocates into the nucleus and the cells complete differentiation and cease proliferation, suggesting that cytoplasmic wild-type p53 participates in pathways of differentiation (Eizenberg et al., 1996) . Thus, the presence of cytoplasmic wild-type p53 does not necessarily de ne an aberrant situation, but is a normal event early in differentiation and development-stages that are also de ned by certain IFP expression patterns (Franke et al., 1982) . Precursor cells of the glial cell lineage express only vimentin. Cells that differentiate into oligodendrocytes cease expression of this IFP, whereas cells following the astrocytic pathway switch on GFAP expression. In an intermediate stage, both IFPs are present in astrocytic cells (Ho and Liem, 1996; Lee et al., 2000) .
Astrocytomas frequently coexpress vimentin and GFAP, a pattern that does not change with increasing anaplasia (Herpers et al., 1986) . In addition, they express nonglial IFPs (Hirato et al., 1994) . In a recent DNA microarray and tissue chip technique analysis, overexpression of vimentin was found in both low-grade astrocytomas (grade II diffuse) and high-malignancy tumors (grades III-IV), except for some glioblastomas (Sallinen et al., 2000) . However, astrocytomas generally seem to be less positive for vimentin than for GFAP (Schiffer et al., 1986) . Well-differentiated human astrocytomas stain less frequently with vimentin antibodies than do anaplastic forms or glioblastomas multiforme (Cosgrove et al., 1989) . In contrast, GFAP was present in all forms in this study and proved to be a regular constituent. Human astrocytomas also express nestin (Dahlstrand et al., 1992) , a class VI IFP. Nestin is characteristic of CNS progenitor cells. It is also present in cells that are in transition from a progenitor stage to glial differentiation, and it costains with vimentin (Messam et al., 2000) . Glioblastomas (grade IV) exhibit a strong expression of nestin, whereas grade II astrocytomas lack this protein, suggest-
Discussion
We screened human primary glioblastomas for expression of tumor suppressor protein p53 and IFPs vimentin and GFAP. Most cases (~70%) within both sample groups proved to be p53 positive in immunohistochemistry, but only 3 of 19 tumors harbored a mutation in the central DNA binding domain of p53. Our ndings correspond to observations of others showing that p53 mutations are rare in human primary glioblastomas and that the number of cases that are p53 positive in immunohistochemistry exceeds those having a p53 mutation Rubio et al., 1993; Vital et al., 1998; Von Eckardstein et al., 1997) . So far we cannot preclude the existence of mutations in exons coding for the amino (exons 2-4) and carboxy (exons 10-11) terminal domains of p53, but these occur at a low frequency (1%-3%) in human tumors (Hussain et al., 2000) .
p53 mutations were absent not only from primary glioblastomas exhibiting cytoplasmic staining but also from tumors with an exclusive nuclear p53 staining reaction. As pointed out by others, not only wild-type but also mutant p53 can be cytoplasmic in human glioblastomas (Ali et al., 1994) . This suggested that cell-speci c features and not the p53 genotype determine the localization of this protein. Our ndings, showing that a cytoplasmic accumulation of wild-type p53 correlates with a certain IFP expression pattern, substantiate this assumption. All of the tumors with cytoplasmic p53 also expressed vimentin and GFAP. In contrast, glioblastomas with an exclusive nuclear p53 were either GFAP or vimentin positive. Thus, when considering IFP expression and subcellular localization of p53 as independent parameters, primary glioblastomas are heterogeneous. When correlated with each other, however, a subpopulation of tumors could be identi ed where the presence of p53 in the cytoplasm was consistently associated with expression of both IFPs. It is not known whether a certain correlation between subcellular localization of p53 and IFP expression is also found with secondary glioblastomas, tumors which have evolved from low-grade astrocytomas and reveal a higher incidence of p53 mutations. At least, secondary glioblastomas with mutated p53 preferentially seem to accumulate the protein in the nucleus (Watanabe et al., 1996) .
Recently we showed that C6 rat glioma cells transfected with a temperature-sensitive mutant p53 (p53 val-135 ) could anchor p53 in the cytoplasm, provided that these cells contained vimentin IFPs (Klotzsche et al., 1998) . A C6 subclone completely lacking cytoplasmic intermediate laments (Röser et al., 1991; Bohn et al., 1993) constantly harbored p53
val-135 in the nucleus. Vimentinde cient cells that were retransfected with an exogenous mouse vimentin protein were again capable of anchoring p53 val-135 to the cytoplasm. The data indicated that the presence of vimentin is decisive for a cytoplasmic localization of p53 in these cells. Furthermore, only vimentinpositive C6 cells can overcome growth suppression by p53 val-135 (unpublished data, W.B., 2001) . In these cells, the wild-type form of p53 val-135 accumulates only transiently in the nucleus after the shift to the permissive temperature and concomitantly induces a transient G 1 arrest. The cells rapidly exclude the wild-type form of ing that nestin expression varies with the degree of malignancy (Dahlstrand et al., 1992) . The data indicate that glioblastomas exhibit an IFP expression pattern that is typical of undifferentiated glial cells. Therefore, primary glioblastomas showing wild-type p53 in the cytoplasm and expressing vimentin and GFAP may have developed from cells arrested in an early stage of astrocyte differentiation. Whether or not inactivation of wild-type p53 associated with cytoplasmic sequestration of the protein is an initial event in tumor development is still unknown.
Normal tissues and tumors that accumulate large amounts of wild-type p53 both have in common the fact that p53 is inactive with regard to growth-suppressive functions. Correspondingly, we observed no differences with regard to the proliferation index between tumors overexpressing wild-type p53 and those that were p53 negative. Also, the presence of cytoplasmic p53 did not correlate with certain clinical features. However, as shown for neuroblastoma cell lines, p53-dependent signaling pathways probably are intact in tumor cells accumulating wild-type p53 in the cytoplasm (Goldman et al., 1996) . Thus, reactivation of cytoplasmic wild-type p53 in primary glioblastomas could be a favorable approach for speci c treatment of this tumor subset.
